Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -13.65% is 14% above its 5-year average of -15.81%, near the high end of its 5-year range (-70.81%–-0.18%).
66.13% above its 12-month average of -40.30%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.81%.
RETURN ON ASSETS (ROA)
-13.65%
RETURN ON ASSETS (ROA) AVG TTM
-40.30%
RETURN ON ASSETS (ROA) AVG 3Y
-22.41%
RETURN ON ASSETS (ROA) AVG 5Y
-15.81%
RETURN ON ASSETS (ROA) AVG 10Y
-10.94%
RETURN ON ASSETS (ROA) AVG 15Y
-2.20%
RETURN ON ASSETS (ROA) AVG 20Y
-1.39%
CURRENT VS TTM AVG
+66.13%
CURRENT VS 3Y AVG
+39.10%
CURRENT VS 5Y AVG
+13.63%
CURRENT VS 10Y AVG
-24.75%
CURRENT VS 15Y AVG
-521.76%
CURRENT VS 20Y AVG
-882.85%
SECTOR MEDIAN · HEALTHCARE
-30.67%
median of 686 covered companies
CURRENT VS SECTOR MEDIAN
+55.50%
vs the sector median at left
Harvard Bioscience, Inc.
Market Cap
$39.10M
Return on Assets (ROA)
-13.65%
TTM Avg
-40.30%
3Y Avg
-22.41%
5Y Avg
-15.81%
Market Cap
$38.35M
Return on Assets (ROA)
-26.45%
TTM Avg
-127.88%
3Y Avg
-142.31%
5Y Avg
-121.77%
Market Cap
$39.90M
Return on Assets (ROA)
11.01%
TTM Avg
4.71%
3Y Avg
-17.75%
5Y Avg
-20.00%
Market Cap
$39.92M
Return on Assets (ROA)
-53.81%
TTM Avg
-31.90%
3Y Avg
-23.26%
5Y Avg
-21.62%
Market Cap
$37.28M
Return on Assets (ROA)
-110.85%
TTM Avg
-107.44%
3Y Avg
-115.17%
5Y Avg
-101.88%
Market Cap
$36.80M
Return on Assets (ROA)
-120.78%
TTM Avg
-168.59%
3Y Avg
-147.82%
5Y Avg
-131.31%
Market Cap
$41.78M
Return on Assets (ROA)
-40.69%
TTM Avg
-38.43%
3Y Avg
-19.21%
5Y Avg
-15.37%
Market Cap
$41.92M
Return on Assets (ROA)
-5.70%
TTM Avg
-13.47%
3Y Avg
-29.01%
5Y Avg
-32.57%
Market Cap
$36.25M
Return on Assets (ROA)
118.69%
TTM Avg
-31.86%
3Y Avg
-49.56%
5Y Avg
-43.59%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Harvard Bioscience, Inc. (HBIO) | $39.10M | -13.65% | -40.30% | -22.41% | -15.81% |
| Incannex Healthcare Limited (IXHL)vs › | $38.35M | -26.45% | -127.88% | -142.31% | -121.77% |
| Nephros, Inc. (NEPH)vs › | $39.90M | 11.01% | 4.71% | -17.75% | -20.00% |
| Metagenomi, Inc. Common Stock (MGX)vs › | $39.92M | -53.81% | -31.90% | -23.26% | -21.62% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.28M | -110.85% | -107.44% | -115.17% | -101.88% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.80M | -120.78% | -168.59% | -147.82% | -131.31% |
| Filana Therapeutics, Inc. (FLNA)vs › | $41.78M | -40.69% | -38.43% | -19.21% | -15.37% |
| Precipio, Inc. (PRPO)vs › | $41.92M | -5.70% | -13.47% | -29.01% | -32.57% |
| Elutia Inc (ELUT)vs › | $36.25M | 118.69% | -31.86% | -49.56% | -43.59% |
| DocGo Inc. (DCGO)vs › | $35.76M | -103.00% | -39.81% | -17.36% | -12.69% |
ROA
-13.7%
ROE
-140.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -70.81% |
| 2024-12-31 | -9.80% |
| 2023-12-31 | -2.49% |
| 2022-12-31 | -6.55% |
| 2021-12-31 | -0.18% |
| 2020-12-31 | -5.00% |
| 2019-12-31 | -2.84% |
| 2018-12-31 | -2.06% |
| 2017-12-31 | -0.79% |
| 2016-12-31 | -4.00% |
| 2015-12-31 | -15.84% |
| 2014-12-31 | 1.73% |
| 2013-12-31 | -1.35% |
| 2012-12-31 | 1.78% |
| 2011-12-31 | 3.01% |
| 2010-12-31 | 15.24% |
| 2009-12-31 | 6.75% |
| 2008-12-31 | 2.06% |
| 2007-12-31 | -1.37% |
| 2006-12-31 | -2.51% |
| 2005-12-31 | -34.64% |
| 2004-12-31 | 1.66% |
| 2003-12-31 | 3.32% |
| 2002-12-31 | 0.69% |
| 2001-12-31 | -6.32% |
| 2000-12-31 | -84.80% |
| 1999-12-31 | -142.75% |
| 1998-12-31 | 0.98% |
